LC/MS Analysis of Clenbuterol In Plasma on Astec® CHIROBIOTIC® T with Phospholipid Removal using HybridSPE® Phospholipid

LC/MS Analysis of Clenbuterol In Plasma on Astec® CHIROBIOTIC® T with Phospholipid Removal using HybridSPE® Phospholipid

Conditions

sample preparation SPE (Solid Phase Extraction)
sample/matrix rat plasma spiked with clenbuterol enantiomers at 10 ng/mL
SPE well plate HybridSPE-Precipitation 96-well Plate, 50 mg/well (575656-U)
sample addition 100 µl spiked rat plasma followed by 300 µl 1% formic acid in acetonitrile. Mix by vortexing the HybridSPE-PPT plate briefly.
elution apply vacuum
column CHIROBIOTIC T, 10 cm x 2.1 mm I.D., 5 µm particles (12018AST)
column temp. 30 C
mobile phase 10 mM ammonium formate in methanol
flow rate 0.3 ml/min
injection 10 µl
detector ABI 3200 QT; ESI(+), MRM: 184/104 m/z (phospholipids); 277.2/203.1 m/z (clenbuterol)

Description

Application The HybridSPE method provides significant improvement in LC-MS baseline.
Categories Analytical Chromatography, Forensics and Toxicology, Chiral Applications, Clinical, SPE Applications, Clinical, Forensic & Toxicology, drugs of abuse, bronchodilators, beta-agonists, Pharmaceutical & Clinical applications, Beta-agonists, Drugs of Abuse
Featured Industry Clinical
Forensics and Toxicology
Pharmaceutical (small molecule)
Legal Information HybridSPE is a registered trademark of Sigma-Aldrich Co. LLC, CHIROBIOTIC is a registered trademark of Sigma-Aldrich Co. LLC, Astec is a registered trademark of Sigma-Aldrich Co. LLC
suitability application for LC-MS, application for SPE

Materials

     
Related Links